Sickle Cell Disease in Children and Adolescents Guideline Development Group - Proposed additional members of the Guideline Development Group to update the WHO Consolidated Guidelines for the Treatment of Common Childhood Illnesses, 2023 (2023)

disclaimer:To improve the management of conflicts of interest and increase public trust and transparency in relation to WHO meetings and activities providing technical/policy advice, names and brief biographies of individuals are taken into account ("Information published") to participate in a Guideline Development Group. convened by WHO are released for public notification and comment.

The published information is provided by the experts themselves and is the sole responsibility of the interested parties. WHO is not responsible for the accuracy, veracity and completeness of the published information provided. Furthermore, in no event shall WHO be liable for any damages related to the use of and reliance on published information.

Comments received by WHO through the public notice and comment process will remain confidential and will be acknowledged by general email notification to the sender. Any comments can be sent to this email address:[email protected]. Comments brought to the attention of WHO through this process are an integral part of WHO's conflict of interest review process and are carefully considered. WHO reserves the right to discuss the information obtained through this process with the relevant expert and disclose the name and affiliation of the provider of such information. After reviewing and reviewing the information received through this process, WHO may, in its sole discretion, take appropriate management actions in accordance with its policies.

Guideline development groups provide technical and/or regulatory advice and recommendations to WHO. Participation in a guideline group convened by WHO does not necessarily mean that the views expressed by the relevant expert are shared by WHO and/or represent decisions or policies established by WHO. The list of participating experts, a summary of the relevant interests disclosed by those experts, and any appropriate mitigation measures taken by WHO in relation to managing conflicts of interest will be made public in accordance with WHO policy.

Record

Significant progress has been made in reducing infant mortality in the past two decades. Despite these advances, an estimated 5.9 million children and young adolescents died in 2021[1]. Most of these deaths are preventable and unevenly distributed, with the majority occurring in Africa and East Asia. The main causes of mortality and morbidity are largely due to problems in the neonatal period. while in the post-neonatal period the main causes are infectious diseases such as lower respiratory tract infections, diarrhoea, malaria and in older children and young adolescents non-communicable diseases such as injuries are the main causes.[2]. Interventions to address them are known and available and will prevent these deaths if they can be delivered equitably and with high quality at a high level of coverage.

The WHO Department of Maternal, Newborn, Child and Adolescent Health and Aging (MCA) has developed guidelines for the clinical management of childhood illnesses to assist health professionals to provide quality care in primary health care and primary hospitals: the integrated management of childhood illnesses(IMCI) Card bookand 2) WHEREChildren's Hospital Care Pocket Book. These tools were last updated in 2013 and 2014, as derivatives of the guidelines for the management of common childhood conditions published in 2012. Both the guide and its derivatives focused primarily on the care of children under 5 years of age. By reshaping the child health agenda within the framework of the Sustainable Development Goals (SDGs), WHO has begun to ensure continuity of services and guidance for optimal care for children throughout their lives, from childhood to adolescence.

The MCA department is now starting a process to update the background guide containing the recommendations that will guide the update of both tools. The recommendations of the new guide will cover, where appropriate, ages 5-9 and 10-14, expanding the age range of both derivatives. The general scope includes the clinical management of common childhood diseases in primary care centers and first reference hospitals. It encompasses clinical evaluation, investigation, diagnosis, treatment, and supportive care for urgent, acute, and chronic conditions common in children and young adolescents. It will address communicable and non-communicable diseases and priority conditions that are the leading causes of mortality or morbidity in children and young adolescents up to 14 years of age, particularly in low- and middle-income countries.

The guideline development process will utilize a comprehensive WHO guideline review committee (GRC) process.[3]including systematic reviews, the development of evidence for decision frameworks and the formation of a Guideline Development Expert Group (GDG) to review the evidence and make recommendations. The scope includes the treatment of asthma in children and young adolescents. acute bronchiolitis? common causes of fever (urinary tract infections, mastoiditis, acute otitis media, chronic otitis media). common noncommunicable diseases (anemia, sickle cell disease, diabetes mellitus); and provide supportive care for the sick child, who will review the administration of oxygen therapy and the diagnosis and treatment of hypoglycemia. The WHO guidelines steering committee has developed a list of design questions for systematic reviews in population, intervention, control, and outcome formats for consideration by the GDG. The final forms of the research questions (including additional questions) are expected to be determined at the first guideline development group (GDG) meeting.

Role of the Guidelines Group

The guideline development group consists of external experts in the field, whose primary task is to develop evidence-based recommendations for the guideline. GDG members participate in the guideline development process and meetings as individuals and not as representatives of the institutions or organizations with which they are affiliated. The GDG is also responsible for finalizing the scope of the key guidance questions. During the guideline development process, members of the GDG will be asked to identify priority outcomes that will guide the collection and review of evidence, review evidence quality profiles, interpret the evidence, and make recommendations for incorporating in the guide.

In 2022, a panel of experts with expertise in a broad range of pediatric and adolescent clinical and public health areas were invited to serve as GDG members for the guideline, with the first GDG meeting in July 2022. Based on feedback From the GDG panel, the MCA section proposes the addition of additional members to the GDG with specific expertise in the epidemiology, research, and clinical management of diabetes mellitus in children and adolescents. The tentative list of GDG members who are specialists, frontline providers and patient representatives is included below:

related links

WHO recommendations for the management of common disorders in children, 2012https://apps.who.int/iris/handle/10665/44774

Pocket Book of Hospital Care for Children: Second Edition, Guidelines for Treatment of Common Childhood Illnesseshttps://www.who.int/publications/i/item/978-92-4-154837-3

Integrated Management of Childhood Illness - Graphic Brochure (March 2014)https://www.who.int/publications/m/item/integrated-management-of-childhood-illness---chart-booklet-(maart-2014)

Report of the meeting on the redesign of health programs for children and youth January 23-25, 2019https://www.who.int/publications/i/item/redesigning-child-and-adolescent-health-programmes

List and biographies of proposed guideline development team members

1. Dr. A.S. A. S. AS. Adekunle D. Adekile
2. doctor An Athalé
3. Dra. Jane Hankins
4. Dr. Jane Makani
5. Dr. Leon Tshilolo

Biographies GDG SCD

Declarations of interest (DOI)

The WHO Secretariat received and reviewed all DOIs submitted by GDG members. In accordance with WHO policy, all declared interests, even if they do not lead to a conflict of interest justifying the partial or total exclusion of the expert, will be disclosed at the beginning of the Guidance Development Group (GDG). so that other members know. Many of the GDG members have extensive research and government experience, as well as specialist knowledge (and WHO consultation) in the areas covered by the Underdevelopment Directive, which are considered relevant and important to the GDG's tasks.

Comment Process on Proposed GDG Members

If you have any comments on the proposed GDG members, please send them to[email protected]before June 7 at 5:00 p.m. Geneva time.